Abstract: The present disclosure provides platforms, systems and methods that may provide a data-driven workflow platform. A method of the present disclosure may comprise: mapping selected data objects to a data storage model of the data-driven workflow platform, where the selected data objects are stored in a data cloud configuration that is operatively coupled to the data-driven workflow platform; and displaying, on a graphical user interface (GUI), a flow for building a cloud application utilizing or managing the selected data objects. The interactive flow comprises at least one graphical element corresponding to a rule for automating an action triggered by a triggering event of the selected data objects.

Abstract: The present invention relates to a NLRP3 variant comprising at least a partial deletion of the PYD. The present invention further relates to a method of screening for a compound that inhibits the NLRP3 inflammasome. The present invention further provides a method comprising the step of administering a compound identified by such a screening method to a subject with a NLRP3-associated inflammatory disorder.

Abstract: The platforms, systems and methods provided herein may provide a data-driven workflow platform. The method comprises: mapping selected data objects to a data storage model of the data-driven workflow platform, where the selected data objects are stored in a data cloud configuration that is operatively coupled to the data-driven workflow platform; and displaying, on a graphical user interface (GUI), a flow for building a cloud application utilizing or managing the selected data objects. The interactive flow comprises at least one graphical element corresponding to a rule for automating an action triggered by a triggering event of the selected data objects.

Abstract: The platforms, systems and methods provided herein may provide a data-driven workflow platform. The method comprises: mapping selected data objects to a data storage model of the data-driven workflow platform, where the selected data objects are stored in a data cloud configuration that is operatively coupled to the data-driven workflow platform; and displaying, on a graphical user interface (GUI), a flow for building a cloud application utilizing or managing the selected data objects. The interactive flow comprises at least one graphical element corresponding to a rule for automating an action triggered by a triggering event of the selected data objects.

Abstract: Apelin receptor modulators can improve physical performance, slow progression of age-related frailty, and can reduce age-related muscle weakness in human patients. This disclosure provides methods for treating muscle conditions using a particular class of apelin receptor modulators (e.g., agonists). The muscle condition can be an age-related muscle condition. Also provided is a method for maintaining and/or increasing muscle mass and/or muscle strength in an elderly subject by administration of the apelin receptor modulator. In some embodiments, the apelin receptor modulator (e.g., agonist) is BGE-105, or a pharmaceutically acceptable salt thereof.

Abstract: The platforms, systems and methods provided herein may provide a data-driven workflow platform. The method comprises: mapping selected data objects to a data storage model of the data-driven workflow platform, where the selected data objects are stored in a data cloud configuration that is operatively coupled to the data-driven workflow platform; and displaying, on a graphical user interface (GUI), a flow for building a cloud application utilizing or managing the selected data objects. The interactive flow comprises at least one graphical element corresponding to a rule for automating an action triggered by a triggering event of the selected data objects.

Abstract: The platforms, systems and methods provided herein may provide a data-driven workflow platform. The method comprises: mapping selected data objects to a data storage model of the data-driven workflow platform, where the selected data objects are stored in a data cloud configuration that is operatively coupled to the data-driven workflow platform; and displaying, on a graphical user interface (GUI), a flow for building a cloud application utilizing or managing the selected data objects. The interactive flow comprises at least one graphical element corresponding to a rule for automating an action triggered by a triggering event of the selected data objects.

Abstract: Apelin receptor modulators can improve physical performance, slow progression of age-related frailty, and can reduce age-related muscle weakness in human patients. This disclosure provides methods for treating muscle conditions using a particular class of apelin receptor modulators (e.g., agonists). The muscle condition can be an age-related muscle condition. Also provided is a method for maintaining and/or increasing muscle mass, muscle function, and/or muscle strength in an elderly subject by administration of the apelin receptor modulator. In some embodiments, the apelin receptor modulator (e.g., agonist) is BGE-105, or a pharmaceutically acceptable salt thereof.

Abstract: This disclosure provides methods for using a particular class of apelin receptor modulators to reduce blood-brain barrier (BBB) permeability in a subject in need thereof, and in particular methods of treatment for a variety of disorders, conditions, and diseases associated with and related to increased BBB permeability. This disclosure also provides methods for using a particular class of apelin receptor modulators to treat a neurodegenerative disease, delirium, and/or dementia in a subject in need thereof. This disclosure also provides methods for using a particular class of apelin receptor modulators to reduce neuroinflammation in a subject in need thereof. In some embodiments, the apelin receptor modulator (e.g., agonist) is BGE-105, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.

Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.

Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.

Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.

Abstract: This disclosure describes systems, methods, and devices related to label based isochronous connection update. A central Bluetooth low energy (BLE) device may send a plurality of labels to a peripheral BLE device during a setup of a BLE communication to notify the peripheral BLE device of one or more labels to be used during the BLE communication. The central BLE device may determine a channel variation between the central BLE device and the peripheral BLE device. The central BLE device may send a first label to the peripheral BLE device to indicate an isochronous (ISO) parameter update that will occur at a first time offset based on the channel variation. The central BLE device may implement the isochronous parameter update at the first time offset based on the channel variation.

Abstract: Methods, apparatus, systems and articles of manufacture to improve Bluetooth low energy streaming connection efficiency are disclosed herein. An example method includes accessing a request received at a first device from a second device, the request requesting set up of an isochronous link between the first device and the second device, the request including a configuration identifier. Whether the configuration identifier identifies a configuration stored at the first device is determined. In response to determining that the configuration identifier identifies the configuration stored at the first device, the isochronous link using the stored configuration.

Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.

Abstract: Systems and methods for recovering unmanned aircraft and controlling post-recovery motion of the aircraft are disclosed herein. An aircraft recovery system for handling an unmanned aircraft in accordance with one embodiment of the disclosure includes a base portion and an elongated aircraft capture member having a first end movably coupled to the base portion and a second, free end opposite the first end. The aircraft capture member includes a first portion and a second portion at a distal end of the first portion and positioned to intercept an unmanned aircraft in flight. The first and/or second portions are generally flexible. The system further includes an energy capture and dissipation assembly operably coupled to the aircraft capture member and positioned to receive at least a portion of the landing forces from the aircraft.

Abstract: Embodiments of the present disclosure include methods, devices and systems for Bluetooth low energy discovery in wireless application service platforms. One example embodiment relates to transmitting, by a first terminal including a radio, a request message for seeking service, receiving, by a peer terminal, the request message for seeking service, transmitting to the first terminal, by the peer terminal, a response frame advertising service including service provider information.

Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.

Abstract: Embodiments of the present disclosure include methods, devices and systems for Bluetooth low energy discovery in wireless application service platforms. One example embodiment relates to transmitting, by a first terminal including a radio, a request message for seeking service, receiving, by a peer terminal, the request message for seeking service, transmitting to the first terminal, by the peer terminal, a response frame advertising service including service provider information.